She is either the very best of the best, hanging on as she did, or in combo with the market dynamics a bit lucky also. But consider as others have that in election years, biotech can get abused by regulatory and direct curtailment of pricing fears.
I do not think it is any benefit to her to upgrade right now, anytime soon given the volatility. If anything she looks like a genius and she will continue to look like one for the time being, imho. She writes up a very good story for Arena's business and shows she likes the company's science and chances if all falls into place, but she has protected herself.